Effective March 1, 2018, new precertification requirements will go into effect for AmeriHealth Pennsylvania members for the following specialty drugs that are eligible for coverage under the medical benefit:

• Durolane^® (hyaluronic acid)
• Ixifi^TM (infliximab-qbtx)
• Lutathera (lutetium [177Lu] oxodotreotide)
• Ogivri^TM (trastuzumab-dkst)
• Pemfexy^TM (pemetrexed)
• TriVisc^TM (sodium hyaluronate)

These changes will be reflected in an updated precertification requirement list, which will be posted to our website prior to these changes going into effect. The availability of the updated precertification list will be announced in a future Partners in Health Update^SM article.